PMID: 9175621Mar 1, 1997Paper

Identification of pore-forming subunit of P-type calcium channels: an antisense study on rat cerebellar Purkinje cells in culture

Neuropharmacology
S GillardD Lodge

Abstract

Treatment of cerebellar neurones in culture with an antisense oligonucleotide (ODN) against alpha1A, reduced the whole-cell P-type calcium channel current relative to mismatch ODN treated controls (p < 0.001). Therefore, AgaIVA (50 nM) reduced whole-cell calcium current in mismatch and antisense treated cells by 70 +/- 4 and 19 +/- 3%, respectively.

Citations

Nov 17, 2004·Neurotoxicity Research·Francis C LauLouise C Abbott
Feb 14, 2002·Progress in Biophysics and Molecular Biology·T E Fisher, C W Bourque
Nov 14, 1997·Trends in Pharmacological Sciences·J M NooneyA Feltz
Apr 4, 2002·The Journal of General Physiology·Stefan I McDonoughBruce P Bean
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·E S Piedras-RenteríaP M Best
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·K JunH S Shin
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·E S Piedras-Rentería, R W Tsien
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·A PintoJ Boot
Apr 6, 2006·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Kylie A ScogganDennis E Bulman
Apr 18, 2002·Journal of Neuroimmunology·Samantha E GillardRichard J Miller
Apr 23, 2005·The European Journal of Neuroscience·M A KampT Schneider
Nov 16, 2007·The European Journal of Neuroscience·Kathryn S RichardsKurt Bommert
Jan 5, 2002·The Journal of Biological Chemistry·Taiji TsunemiTsutomu Tanabe
Jul 19, 2000·Journal of Neurophysiology·L S DoveW H Griffith
Jul 22, 1999·Annals of the New York Academy of Sciences·S M SmithR W Tsien
Jul 22, 1999·Annals of the New York Academy of Sciences·H Moreno Davila

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.